The OBIO® 2023 Early Technology Showcase(ETS) will feature presentations from Canada’s leading research institutions and healthcare organizations to global investors. ETS partners are invited to present the most promising technologies as well as introduce projects with the greatest potential for commercialization in their research portfolios and emerging health science companies.
Here is a snapshot of what you will see:
Presenting organizations
More partners & their spin-outs to be announced soon.
Dalhousie University is Atlantic Canada’s premier research-intensive university. Dalhousie and its affiliated hospitals are home to research centres, institutes, groups and units at the forefront of innovation across health and life sciences and will highlight recent developments in therapeutics and medtech.
Hollo Medical is reducing the burden of chronic respiratory diseases by transforming the current thermos sized valved holding chamber, relied upon by millions of inhaler users, into a device that achieves optimal drug deposition and can comfortably fit in a pocket.
Hamilton Health Sciences (HHS): a world-renowned hospital for healthcare research, HHS is a community of 15,000 staff, physicians, researchers and volunteers that provide specialized, advanced care to southwestern Ontario residents. The only hospital in Ontario that cares for all ages, from pre-birth to end-of-life, HHS offers world-leading expertise in many areas, including cardiac and stroke care, cancer care, palliative care and pediatrics.
McGill University is one of Canada's best-known institutions of higher learning and one of the leading universities in the world, recognized for the excellence of its teaching and research programs. McGill has a long tradition of innovation that includes the invention of the artificial blood cell. Today its professors are building the new field of epigenetics, and driving human achievement in every field imaginable.
Live Cell Technologies Canada provides a turn-key platform for measuring cell contractile forces. These forces are dysfunctional in diverse diseases, from asthma to cancer and heart disease, thus their quantification offers novel insight into diagnostics and drug-discovery therapeutics. Clients using our technologies include Pfizer, Amgen, and Astrazeneca.
DendroTEK Biosciences develops and sells advanced surface coatings that deliver game-changing support for long-term cell culture.
McMaster University is a leader in health sciences research, and is recognized internationally in biomedical innovation. McMaster University, one of four Canadian universities listed among the Top 100 universities in the world, is renowned for its innovation in both learning and discovery.
AIMA Laboratories is a Canadian FemTech company that has developed a home test for endometriosis.
Esphera SynBio is developing proprietary technologies to generate designer therapeutic exosomes either in vivo/in situ or in vitro primarily as immunotherapies for cancer or infectious disease.
Synmedix is developing an innovative platform to overcome antibiotic resistance, one of the biggest threats to global health.
Ontario Genomics is a not-for-profit organization leading the application of genomics-based solutions across key sectors to drive economic growth, improved quality of life and global leadership for Ontario. Ontario Genomics contributes to Ontario’s lively life sciences start-up community through direct investments and has helped more than 30 startup companies to scale up and commercialize, funding innovation projects to the tune of $1.4B since 2000.
Liberum Bio is an early-stage SOSV-backed company (currently raising their seed round) focused on speeding up protein discovery via their proprietary cell-free protein synthesis platform. Their technology is the fastest (30x) and cheapest (4x) way to synthesize proteins like enzymes and nanobodies. There are 30+ institutions (labs and companies) making proteins on their technology so far. They are planning to use the seed round to scale their ability to make 1000s of proteins per month, and to scale their AI discovery component to help speed up protein engineering efforts.
Stem Cell Network (SCN) is a national not-for-profit that supports stem cell and regenerative medicine research and training across Canada. SCN’s goal is to translate science from bench to bedside. SCN is funded by the Government of Canada and works in partnership with industry, health charities and research institutions to build Canada’s emerging regenerative medicine sector.
Axolotl Biosciences provides turn-key reagents such as functional bioinks, 3D tissue models, and services in the field of 3D bioprinting.
Mesintel Therapeutics is decoding fibroblast biology to create superior therapeutics.
Morphocell Technologies is a regenerative medicine company developing an extensive therapeutic platform based on its stem cell-derived engineered tissues for organ replacement therapy. Through an allogeneic approach, strong preclinical data in small and large animals and key hurdles in manufacturing already de-risked, Morphocell is rapidly approaching the clinical phases.
St. Joseph's Healthcare Hamilton (SJHH): a premier academic health science and research centre, SJHH delivers high-quality, evidence-based care to patients in Hamilton-Niagara-Haldimand-Brant and beyond. Home to more than 5,000 staff, 700 physicians and 1000 volunteers, St. Joseph's is a multi-site, regional, tertiary centre, renowned for its strength in respiratory care, kidney and urinary care, mental health and addictions, surgical services, cancer surgery and women’s and infants’ care.
Toronto Innovation Acceleration Partners (TIAP) is a leading provider of commercialization expertise, early-stage funding, and deal-brokering with industry and private investors in the health sciences domain. TIAP is a member-based organization with the mandate to drive the commercialization of their most promising research breakthroughs.
Member institutions:
The Centre for Addiction and Mental Health (Toronto, Ontario) – Canada’s leading mental health research center featuring research on depression, schizophrenia, bipolar disorder and dementia.
The Hospital for Sick Children (SickKids) champions the identification, development and commercialization of cutting-edge health research, technology and innovations developed by its scientists and clinicians. SickKids partners with industry and investors to translate research into products that have health, social and economic benefits.
The Lunenfeld-Tanenbaum Research Institute (LTRI) is Sinai Health’s engine of innovation and discovery. It is one of the world’s top biomedical research institutes and home to scientists who are leaders in the fields of system biology, neurodevelopment, women’s and infants’ health, regenerative medicine, and complex diseases such as cancer, diabetes, musculoskeletal conditions and more.
University Health Network (UHN) is Canada’s largest research hospital and is consistently ranked number one on the list of Canada's Top Research Hospitals. UHN has strengths in immunology and cell-based cancer therapies.
Unity Health Toronto, comprised of Providence Healthcare, St. Joseph’s Health Centre and St. Michael’s Hospital, is routinely ranked as a top Canadian hospital network and a national leader in health research.
Genetics Adviser: Patients’ digital guide to their genetic testing journey Save time and money. Improve patient experience.
The University of Toronto is Canada’s top university and one of the world’s top research-intensive universities. The University of Toronto Early Stage Technology (UTEST) Program provides support to University of Toronto entrepreneurs to create research-based companies founded on cutting-edge research from the University of Toronto and affiliated hospitals.
The University of Alberta in Edmonton is one of the top teaching and research universities in Canada, with an international reputation for excellence across the humanities, sciences, creative arts, business, engineering and health sciences. The Health Innovation Hub is a community incubator for innovators and entrepreneurs working towards better human health outcomes.
Applied Pharmaceutical Innovation (API) is a national not-for-profit that helps commercialize innovation by supporting life science companies in an industry-led collaborative network model.
48Hour Discovery is a leading peptide-based platform accelerating discovery of novel molecules for the delivery of therapeutic payloads, with a focus on bringing targeted radiopharmaceuticals to market faster than ever before.
Nanostics is a clinical-stage company that uses machine learning (ML) to help bring clarity to health care decisions.
University of British Columbia (Vancouver, British Columbia) – is amongst the top 40 global research universities with recent developments in cell-surface engineering to reduce organ rejections and multiple mRNA spin-off companies including Acuitas Therapeutics and AbCellera.
